The FDA has officially green-lighted the Remicade biosimilar Inflectra, a med from South Korea's Celltrion and Pfizer's ($PFE) Hospira. But will the knockoff be able to capture the same kind of market share from Johnson & Johnson ($JNJ) that it's been stealing in Europe from Merck & Co. ($MRK)? Depends who you ask. More from FiercePharma
> Johnson & Johnson ($JNJ) inked a $85 million deal to develop and sell Tesaro's experimental prostate cancer pill niraparib. Report
> Amphastar Pharmaceuticals ($AMPH), which has come in for criticism for the price of its overdose antidote naloxone, agreed to give Connecticut a $6 rebate for each dose purchased by a state or municipal agency. Report
> The cost of insulin treatments for diabetes rose by nearly 200% from 2002 to 2013, the Journal of the American Medical Association reports, as expensive new analog treatments supplanted older human insulins. Report
> Shire ($SHPG) released top-line Phase III data on its ADHD drug candidate SHP465 showing that the drug met its primary goal for improving symptoms in children and adolescents. Report
> Hedge funder Bill Ackman is set to explain a 25% quarterly loss to his investors Wednesday, with his bad bet on Valeant Pharmaceuticals ($VRX) first in line. Report
And Finally... Worldwide diabetes cases hit 422 million as the disease mushrooms in the developing world. Report